RiaSTAP is a Intravenous Injection, Powder, Lyophilized, For Solution in the Plasma Derivative category. It is labeled and distributed by Csl Behring Gmbh. The primary component is Fibrinogen Human.
Product ID | 63833-891_129234e9-6d7e-4fa8-81a6-fb354c18f254 |
NDC | 63833-891 |
Product Type | Plasma Derivative |
Proprietary Name | RiaSTAP |
Generic Name | Fibrinogen Human |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2009-01-16 |
Marketing Category | BLA / BLA |
Application Number | BLA125317 |
Labeler Name | CSL Behring GmbH |
Substance Name | FIBRINOGEN HUMAN |
Active Ingredient Strength | 1300 mg/50mL |
Pharm Classes | Human Blood Coagulation Factor [EPC],Increased Coagulation Activity [PE],Blood Coagulation Factors [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2009-01-16 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125317 |
Product Type | PLASMA DERIVATIVE |
Billing Unit | EA |
Marketing Start Date | 2009-01-16 |
Marketing Category | BLA |
Application Number | BLA125317 |
Product Type | PLASMA DERIVATIVE |
Billing Unit | EA |
Marketing Start Date | 2015-10-15 |
Ingredient | Strength |
---|---|
FIBRINOGEN HUMAN | 1300 mg/50mL |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RIASTAP 77892481 3852693 Live/Registered |
CSL Behring GmbH 2009-12-14 |
RIASTAP 77434377 3655552 Live/Registered |
CSL Behring GmbH 2008-03-28 |